Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

https://ashpublications.org/blood/article/doi/10.1182/blood.2019003471/430032/Mutational-profile-and-benefit-of-gemtuzumab Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Our clinical practice and SOP for AML elderly just published. https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2019003662/429643/Is-There-an-Optimal-Conditioning-for-Older?redirectedFrom=fulltext Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

https://ashpublications.org/blood/article/doi/10.1182/blood.2019002959/430249/Molecular-MRD-status-and-outcome-after Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Λοιμώξεις από JCV και BKV σε ανοσοκατεσταλμένους ασθενείς. Presenter: Dr Liga Participants: Prof.Spyridonidis, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Discrepancies between premortem clinical diagnoses and postmortem  autopsy diagnoses were evaluated. Of 185 patients who underwent autopsy,  35 patients (18.8%) had a total of 41 missed infections. Five patients (2.7%) had >1 missed infection. Of the 41 missed infections, 18 (43.9%) were viral, 16 (39.0%) were fungal, 5 (12.2%) were...

We decided a policy change  and accorrdigly we write the new SOP. MM  patients will receive non cryopreserved stem cell grafts. Presenter: Prof. Spyridondiis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou

A phase II study if vedo in GvHD prevention was presented. This is of  major importance since we run the phase III vedo study. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou

Results of the Prospective Randomized HOVON-96 Trial in Recipients of  Matched Related and Unrelated Donors were presented in ASH 2019, plenary  session PTCY is better than CSI standrd treatment https://ashpublications.org/blood/article-abstract/134/Supplement_1/1/427807/Post-Transplantation-Cyclophosphamide-after?redirectedFrom=fulltext Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Verigou

General principles - We use the lowest effective dose of prednisone or methylprednisolone. - We use topical therapy to supplement systemic treatment. (eg oral budesonide together with beclomethasone) -We use follow-up endoscopy to evaluate the response to treatment in patients with persistent diarrhea. Absence of clinical or...

NPM1_Spyridonidis_EAE_2019 Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou

A paper illustrating the hardle in making decisions in BMT. Presenter: Prof. Spyridonidis  Participants: Dr Liga, Dr Spyridis, Dr Verigou